

Introduction

Founded in 2002, Future Health Biobank is one of the largest and most experienced stem cell banks in Europe, having stored in excess of 1,000,000 umbilical cord stem cell samples for more than 300,000 families across over 94 countries worldwide.

Future Health Biobank operates a state-of-the-art laboratory at its primary headquarters in the UK, with a second purpose-built GMP-grade laboratory in Switzerland.

Future Health laboratories are of the highest quality, highly regulated, and operate to Good Manufacturing Practice (GMP) standards. They are licensed and accredited by the Human Tissue Authority, the Medicines and Healthcare products Regulatory Agency (MHRA), Swiss Medic, OFSP, ISO 9001, and the American Association of Blood Banks (AABB).

Future Health Biobank is well positioned to expand both its existing services and introduce new offerings through its international sales network, which includes offices in more than 40 countries.

In 2016, Future Health Biobank launched a diagnostics division, introducing innovative new screening tests in response to rapid growth in the sector. That same year, it became the world's most accredited stem cell bank.

In 2023, Future Health inaugurated a state-of-the-art, GMP-grade multiple cleanroom facility in the United Arab Emirates, located in the dynamic Dubai Healthcare City. This advanced facility features meticulously controlled environmental and operational conditions to minimize contamination risks and ensure process integrity, in full compliance with rigorous GMP quality standards.

Equipped with cutting-edge technology and monitoring systems, the facility specializes in stem cell duplication, manufacturing, cryogenic storage, and now also includes stem cell and exosome production. These enhanced capabilities support the development and safe application of next generation stem cell therapies and regenerative medicine. The facility offers world-class therapeutic services, premium amenities, and robust collaboration opportunities for clinical and research advancement.

Products and Services



*Umbilical Cord Blood
& Placenta Banking*

*Adipose-Tissue Derived Stem
Cell Banking & Culturing*



*Human Mesenchymal Stem
Cell-Derived Exosomes*





Part of the **Future Health Group**


A New Era of Stem Cells Banking & Regenerative Medicine






Company summary


Successfully storing more than **1000,000** samples for over **300,000** families from over 94 different countries worldwide













































Company development






Our international presence

Albania	Bahrain	Bosnia & Herzegovina	Bulgaria	Canada	Cyprus	Estonia	France	Germany	Ghana
									
Greece	Hong Kong	Hungary	Ireland	Italy	Jordan	Kenya	Kosovo	Kuwait	Latvia
									
Lebanon	Macedonia	Malta	Montenegro	Morocco	Pakistan	Portugal	Qatar	Romania	Russia
									
Saudi Arabia	Serbia	Slovenia	Spain	Sweden	Switzerland	Turkey	Ukraine	UAE	United Kingdom
									



Laboratories

- The only cord blood bank in the world to own and operate laboratories in the UK, UAE dubai health care city and Switzerland
- Laboratories accredited to the highest standards
- Provide disaster recovery contingencies to each other as samples can be sent to either laboratory





Laboratories

- Fully operational GMP standard laboratories with clean room facilities
- Exceptional levels of quality and accreditation
- Operates all year round
- Onsite 24/7 security presence
- Real time sample monitoring system
- Insurance backed disaster recovery program
- Storage capacity for over 2 million cord blood units





Samples released

- Future Health Biobank have released 1000 samples for treatment of conditions such as Cerebral Palsy, Fanconi's Anaemia, Severe Combined Immunodeficiency (SCID), Beta Thalassemia, Diamond Blackfan Anaemia and other regenerative medicine applications
- These samples have been released for transplantation to the US, Europe and the Middle East
- Samples released by Future Health Biobank have been used by both donors (autologous use) and related family members (allogeneic use)
- Cord blood released to treat: Beta Thalassemia, Scid, Fanconi's Anaemia, Autism, Cerebral Palsy, Diamond Black Fan Anaemia
- Cord tissue sample released to the US in 2016 for diagnostic investigative purposes



Our first successful story

Patient: Laith Abu Areesh.

Illness: Fanconi's Anemia, an autosomal recessive disorder that can lead to bone marrow failure, which is life threatening.


Procedure: The teenager's younger sister was born in 2010. Her cord blood was collected at birth, processed and cryopreserved by Future Health Biobank. She was a HLA match to her brother. The sample of cryopreserved cord blood was thawed out and then infused without any additional processing.

Outcome: The procedure was success and Laith had no serious complications. He was subsequently released from the hospital and today continues to lead a normal and healthy life.



Our unique services

- Umbilical cord blood, cord tissue & placenta storage
- Adipose stem cells storage & expansion
- Exosome production





Our collection kits



Thermally insulated
transportation box

**Do not throw
away**



Umbilical cord blood
collection bag




Alcohol wipes for
disinfection



Tempmate data logger



Sterile gauze to
clean the cord prior to
disinfection



Plastic zip-lock bag with
absorbent towel for cord blood
collection bag



Security seals



Bio-pouch



Maternal blood
collection tubes



Label for the cord
blood bag



Vacutainer®
needle and adaptor




Procurement
report



Medical history
questionnaire

**Extra for cord
tissue only**



A 50ml cord
shipping tube.
A 25ml saline
solution sachet.



Preservation
tablet



Placenta



ADIPOSE-TISSUE DERIVED STEM CELLS


Explore the Power of Your Own Stem Cells



The Power of **YOUR OWN** Adipose-Derived Stem Cells

Experience the natural healing power of your own body with fat-derived stem cells. Your own body's tissue holds regenerative cells that can support smoother skin, faster recovery, and relief from joint discomfort. These stem cells, drawn directly from your body, promote tissue repair and rejuvenation, making it a safe and personalized wellness option. From cosmetic treatments to orthopedic support, harnessing your own stem cells can enhance your health and vitality in a natural, effective way. Embrace the future of wellness with your body's unique regenerative power.

Future Health offers stem cell therapy using cells extracted from your own Fat Tissue. The natural results achieved through this treatment are unmatched by any other method.



Collection

A small sample (20 cc) of fat is obtained through a minimally invasive outpatient procedure.

Cell Extraction

The collected fat is processed at Future Health Laboratories, where stem cells are isolated and expanded over two weeks.

Cell Expansion

Cell Expansion
Up to 20 vials of stem cells are produced, available for immediate or future treatments.

Your Care Journey STEP-BY-STEP

Treatment

Cells can be used for immediate therapy or stored for future use.

Banking

Unused vials are cryopreserved for years, ready for future treatments.

Application

Cryopreserved cells can be thawed for additional treatments as needed.



Future FACE

Future Face offers a cutting-edge solution for skin and facial rejuvenation using stem cell technology to restore youthful, radiant skin. This non-invasive treatment taps into the power of stem cells to repair and regenerate, targeting signs of aging at the cellular level.

How Future Face Works

- **Cell Regeneration:** Stimulates skin cell repair with growth factors and proteins, improving overall structure.
- **Collagen Boost:** Enhances collagen and elastin production for firmer, more elastic skin.
- **Tissue Repair:** Reduces inflammation and hydrates, supporting the skin's natural barrier.

What You'll See

- Diminished wrinkles and fine lines.
- Improved texture and tone.
- Long-lasting, natural results without surgery.

Choose Future Face for a safe, effective alternative to Botox and facelifts, achieving a youthful look with lasting effects.

Anti-Aging Skincare



Future HAIR

How Future Hair Works

- Follicle Regeneration: MSCs stimulate new hair growth and strengthen existing strands.
- Improved Blood Flow: Enhances scalp circulation, delivering nutrients and oxygen to hair follicles.
- Reduced Hair Loss: Addresses inflammation to prevent thinning and loss.

What You'll See

- Thicker, fuller hair with increased density.
- A safe, non-invasive alternative to hair transplants.
- Long-lasting, natural results for a youthful hair appearance.

Future Hair is a breakthrough in hair care, harnessing the regenerative power of mesenchymal stem cells to naturally restore and rejuvenate your hair.



Hair Loss



Future ORTHO

Future Ortho uses adipose-derived stem cells (ADSCs) to treat joint pain and regenerate cartilage and bone in knees, hips, and shoulders, leveraging the body's natural healing abilities.

How Future Ortho Works

- **Stem Cell Injection:** ADSCs are harvested from the patient's own fat tissue and injected into the affected area.
- **Tissue Regeneration:** Stem cells promote cartilage and bone repair, reduce inflammation, and improve joint function.
- **Enhanced Healing:** ADSCs can become cartilage and bone cells, repairing degeneration and relieving pain.

What You'll See

- **Pain Relief:** Reduces joint pain by restoring damaged tissue.
- **Improved Mobility:** Enhances joint function for easier movement.
- **Minimally Invasive:** Non-surgical treatment with faster recovery.
- **Long-Term Results:** Supports sustained healing, reducing the need for surgery.

Cartilage & Bone Degeneration

Future ESTRO

Future Estro uses stem cell technology to rejuvenate the female genital area and address premature ovarian failure, providing relief from vaginal dryness, discomfort, urinary incontinence, and early menopause symptoms.

How Future Estro Works

- **Stem Cell Injections:** Cells from the patient's fat tissue are injected to promote regeneration.
- **Tissue Regeneration:** Boosts collagen and elastin for improved elasticity and moisture.
- **Ovarian Function:** Aims to restore hormonal balance and support ovarian health.

What You'll See

- **Enhanced Vaginal Health:** More moisture and elasticity, reducing discomfort.
- **Better Bladder Control:** Strengthens pelvic muscles to reduce incontinence.
- **Ovarian Rejuvenation:** Supports hormone balance and fertility.
- **Quick Recovery:** Non-surgical treatment with minimal downtime.

Future Estro is a safe, non-invasive solution that revitalizes female reproductive health and well-being, harnessing the regenerative power of stem cells for effective and long-lasting results.



Premature Ovarian Failure & Female Rejuvenation



Future ANDRO

Future Andro uses advanced stem cell therapy to treat erectile dysfunction (ED) and enhance men's sexual health, offering a natural, non-surgical solution.

How Future Andro Works

- **Stem Cell Therapy:** Adipose-derived stem cells are injected into penile tissue to boost regeneration.
- **Cell Activation:** Promotes new blood vessel growth and repairs damaged tissue to improve erectile function.
- **Long-Term Benefits:** Gradual improvement in sexual performance and tissue health over time.

What You'll See

- **Better Erectile Function:** Easier to achieve and maintain an erection.
- **Enhanced Stamina:** Supports longer-lasting sexual performance.
- **Improved Circulation:** Boosts blood flow for a stronger natural response.
- **Quick Recovery:** Minimally invasive with faster recovery than traditional treatments.

Future Andro offers a safe, non-surgical way to restore sexual health and confidence, harnessing stem cell technology for long-lasting improvements in men's vitality.

Erectile Dysfunction and Men's Sexual Health

Future IV

How It Works

- **Anti-Inflammatory Action:** MSCs help reduce systemic inflammation, targeting and soothing areas with underlying damage.
- **Growth Factor Secretion:** MSCs release growth factors that stimulate tissue repair and collagen production, essential for healthier skin and muscle recovery.
- **Immunomodulation:** MSCs balance immune responses, aiding in the prevention of tissue damage and fostering general health.

What You'll See

- **Skin Health:** Improved skin elasticity, hydration, and a reduction in wrinkles.
- **Joint and Muscle Recovery:** Enhanced physical resilience, reduced inflammation, and improved mobility.
- **Overall Vitality:** Increased energy and a sense of well-being from cellular and systemic rejuvenation.





Full-Body Rejuvenation



EXOFUTURE

Exosome Therapy






Future Health's exosomes, derived from adipose-derived mesenchymal stem cells (MSCs), are naturally occurring nano-sized vesicles that play a critical role in cell communication and regeneration. These exosomes contain key bioactive molecules, such as growth factors and proteins, which are essential for tissue repair and immune modulation.

How It Works

- **Targeted Delivery:** Exosomes are capable of targeting damaged tissues, delivering therapeutic molecules directly to areas in need of healing.
- **Anti-Inflammatory Action:** They help reduce inflammation, supporting the regeneration of tissues affected by chronic inflammation or injury.
- **Cellular Regeneration:** By stimulating cell growth and tissue repair, exosomes aid in the rejuvenation of skin, joints, and other tissues, promoting faster healing and improved function.

These exosomes are used in aesthetic and therapeutic treatments, offering regenerative benefits like skin rejuvenation, joint repair, and overall tissue regeneration.

Future Health ensures the highest quality and potency of its exosome products, maintaining their biological activity for maximum therapeutic effect.





Future GLOW

Future Glow uses exosomes from stem cells to rejuvenate skin, enhancing cellular repair and hydration for a youthful appearance.

How It Works

- Regenerative Exosomes: Stimulate collagen, improving texture and hydration.
- Cellular Renewal: Boosts cell turnover and elasticity, reducing inflammation.

What You'll See

- Radiant, youthful glow with brighter skin.
- Reduced wrinkles and improved firmness.
- Quick recovery with long-lasting, natural results.

Future GROW

Future Grow uses stem cell-derived exosomes to activate hair follicles and promote healthy growth.

How It Works

- Exosome Application: Targets dormant follicles for cellular repair.
- Follicle Stimulation: Enhances nutrient delivery to strengthen roots.

What You'll See

- Fuller, thicker hair with increased volume.
- Less hair thinning and breakage.
- Safe, non-invasive treatment with no downtime.



Future JOINT

Future Joint is a non-surgical therapy that uses exosomes to promote healing and regeneration in damaged joints.

How It Works

- Targeted Healing: Exosomes, tiny particles derived from stem cells, are injected into the joint.
- Regenerative Support: They deliver healing signals that stimulate tissue repair, reduce pain, and promote cartilage regeneration.

What You'll See

- Short-Term: Reduced pain and inflammation.
- Long-Term: Improved joint function, enhanced mobility, and tissue regeneration.



Future VITALITY

Future Vitality is an IV treatment that infuses exosomes for comprehensive cellular repair and anti-aging benefits.

How It Works

- Cellular Regeneration: Delivers growth factors body-wide for enhanced cell repair.
- System-Wide Benefits: Supports healing and reduces inflammation.

What You'll See

- Boosts energy and vitality.
- Promotes anti-aging by rejuvenating cells.
- Aids holistic recovery and strengthens immunity.





Us

Superior tissue repair



Consistent quality



Tailored for clinical needs



Low immunogenicity



High growth factors & Repair-specific proteins
regenerative miRNAs



VS.

Limited repair potential



Inconsistent production



Non-specific applications



Them

Higher immune risk



Low growth factors & generic RNA content



Non-specialized proteins




A close-up, high-angle shot of a woman's face. She is smiling, showing her teeth, and looking upwards and to the right. Her right hand is raised, with her fingers gently touching the skin under her left eye. The lighting is soft and warm, highlighting the texture of her skin and the brightness of her smile. The background is dark and out of focus.

Small but Mighty,
Restoration to
every cell



Human Mesenchymal Stem Cell-Derived Exosomes

Pioneering Cell-Free Regenerative Solutions with Human Mesenchymal Stem Cell-Derived Exosomes



What Are Exosomes?

Exosomes are nanosized extracellular vesicles (30–150 nm) secreted by cells, including Mesenchymal Stem Cells (MSCs). They serve as intercellular messengers, delivering proteins, lipids, mRNA, and microRNA to target cells, and influencing a wide range of physiological and regenerative processes.

Why Human Mesenchymal Stem Cell-Derived Exosomes?

Introducing Our next-generation, high-purity exosomes derived from human umbilical cord Mesenchymal Stem Cell — a powerful, cell-free solution that delivers the regenerative and immunomodulatory benefits of stem cells without the complexity of live-cell therapy.

Backed by purity, safety, and ease of use, our exosomes offer maximum healing potential, reduced immune risk, and simplified storage and delivery. Pure. Potent. Proven. The future of advanced biologics is here.

Our Latest Innovation
EXOFUTURE
Human Mesenchymal Stem
Cell-Derived Exosomes





Key Features

Mesenchymal Stem Cells-Derived Exosomes – At a Glance

- Cell-free and non-replicative
- Rich in growth factors and anti-inflammatory signals
- Naturally targeted to damaged tissues
- Easily stored, transported, and administered
- Lower risk of immune rejection or tumorigenicity

Source & Processing

- Sourced from Wharton's Jelly-derived Mesenchymal Stem Cells (WJ-MSCs)
- Cultured under GMP-compliant conditions
- Processed via precipitation, and quality control
- Standardized and characterized for purity and safety

Aesthetic Applications of MSC-Derived Exosomes

1- Skin Rejuvenation & Anti-Aging

- Reduces fine lines and wrinkles.
- Boosts collagen and elastin production.
- Improves skin tone, texture, and hydration.

2- Acne & Scar Repair

- Reduces inflammation and redness.
- Accelerates skin healing.
- Fades acne scars and blemishes.

3- Hyperpigmentation & Skin Brightening

- Evens skin tone.
- Diminishes dark spots and discoloration.
- Promotes radiant, glowing skin.

4- Hair Restoration

- Stimulates hair follicle regeneration.
- Promotes hair growth and thickness.
- Reduces scalp inflammation.

5- Post-Treatment Recovery

- Enhances healing after microneedling, laser, or chemical peels.
- Reduces downtime, redness, and irritation.
- Speeds up tissue regeneration.

6- Stretch Marks & Skin Firming

- Supports dermal repair.
- Improves elasticity and tightness.
- Minimizes the appearance of stretch marks.



Product Format & Quality



Our Exosome Product Range:

- Standard research-grade exosomes.
- Clinical-grade (GMP-compliant) exosomes – under regulatory development.

Available Formats:

- 25 Billion Exosomes from human mesenchymal stem cells in 5ml vials.

Quality Assurance:

- Nanoparticle Tracking Analysis (NTA).
- Protein quantification (BCA assay).
- Flow cytometry (CD9, CD63, CD81 markers).
- Sterility.



Why Choose

FUTURE HEALTH GCC?

- Over 22 Years of Expertise in Stem Cell Science.
- Expert Team in Stem Cell & Exosome Technologies.
- ISO & GMP-Compliant Manufacturing Facilities.
- Cutting-Edge R&D Pipeline with Proprietary Protocols.
- Customized Solutions for Research & Clinical Partners.
- Global Presence – Operating in the UAE, Switzerland, and the UK.



***Take a 4D Tour of Our
State-Of-The-Art Stem
Cells Facility.***



**SCAN
ME!**



BEFORE



AFTER



THE POWER OF
***Mesenchymal Stem Cells-
Derived Exosomes***

Mesenchymal Stem Cells-Derived Exosomes

VS

Plant-Based


Feature	Mesenchymal Stem Cells-Cultured Exosomes	Plant-Based Exosomes
Source	Cultured mesenchymal stem cells	Fruits, herbs, vegetables
Cost	Higher (GMP production)	Low
Safety	Very safe – Cell-free	Very safe
Targeting Capacity	Tissue-targeted (immune, neural, etc.)	Non-specific
Main Use Cases	Cosmetics, wellness, Regenerative medicine, clinical use	Cosmetics, food, wellness
Immune Modulation	Strong	Mild
Clinical Validation	Strong and growing	Limited
Customization	High (preconditioning, genetic edits)	Minimal

Exosome Isolation: Precipitation Methods




Supernatant Collection

Collect culture media containing exosomes.



Centrifugation

Remove cells and debris via sequential spins.



Polymer Addition

Add Polymer to promote exosome aggregation.



Incubation

Incubate to allow exosome precipitation.



Centrifugation

Pellet exosomes by centrifugation.



Washing & Resuspension

Clean pellet and resuspend in buffer for testing or -80°C storage.

Because Quality in Process, Purity, Potency, & Efficacy Matter.



Future Health GCC exosomes are stored at **-80°C** in digitally monitored freezers to ensure purity, stability, and performance.

- **Preserved Efficacy** – Bioactive molecules stay intact.
- **Long-Term Stability** – Effective for months or years.
- **No Aggregation** – Maintains particle integrity.
- **24/7 Monitoring** – Ensures clinical-grade safety.

Powerful. Reliable. **Ready When You Are.**

TwinCool



Timeless Beauty,
**POWERED BY
EXOSOMES.**

Changing Room



Sample receiving



Cleanroom



Cleanroom



Cleanroom



Cleanroom



Cleanroom



Sterilization Room



Laboratory



Laboratory



Laboratory



Quality Control Room



Microbiology



Pass Box



Vision Panel



Internal Cryogenic





Accreditations and Licenses

Future Health Biobank is the world's most accredited stem cell bank. Generally regarded by its peers as the most innovative, highly considered centre of excellence for quality and service within the stem cell banking industry. The three laboratories are licensed and accredited to the highest level and operate to GMP standards.



AABB (formerly American Association of Blood Banks) accreditation
Number: 138834
Date received: July 2016



Human Tissue Authority (HTA) License
Number: 22503
Date received: April 2006



GMP certification delivered by Swissmedic
Number: 500028
Date received: June 2013



Swissmedic License
Number: 500028
Date received: June 2013



GMP (Good Manufacturing Practices)
Number: QCAS-FHG-24-051581714
Date received: December 2024



ISO:9001 Quality Management
Number: 29, 31, 34, 38
Date received: July 2024



Medicines and Healthcare products Regulatory Agency (MHRA) Blood Establishment Authorisation
Number: 21314
Date received: November 2004



Federal Office Public Health Authorization
Number: BS2013-nTxZ093-N0-V00
Date received: December 2013



Prestigious Queen's Award for Enterprise and International Trade
Number: n/a
Date received: April 2010



ISO:9001 Quality Management
Number: FS 554566
Date received: January 2010



Dubai Health Authority Stem cells processing license
Number: 7381206



ISO:15189:2022 Medical laboratories
Number: QCAS-FHG-24-051581646
Date received: October 2024

CERTIFICATE OF COMPLIANCE



This is to certify that

FUTURE HEALTH GCC FZ LLC

Building 64 – Al Razi Medical Complex, Ground Floor 8R3-9R8, Dubai,
UAE, P.O. BOX - 336509

is in compliance with the requirements of the following standard

GMP
(Good Manufacturing Practices)

SCOPE OF CERTIFICATION

- Harvesting, Isolation, Expansion, and Transplantation of Autologous-Derived Stem Cells (ADCS) and Mesenchymal Stem cells
- Collection, Processing, Testing, storage and release of Human Umbilical Cord Blood and Human Birth Tissue Stem cells for Transplantation

Certificate Number : **QCAS-FHG-24-051581714**

Initial Certification Date : **04 Dec 2024**

Date of Expiry : **03 Dec 2027**

1st Surveillance Date : **04 Nov 2025**

2nd Surveillance Date : **04 Nov 2026**

Verify the Certificate: <https://gaafs.us/site/search/>



Issued by QCAS Certifications Inc.


Managing Director

Certificate of Registration



This is to certify that the Quality Management System of

FUTURE HEALTH GCC FZ LLC

Building 64 - Al Razi Medical Complex, Ground Floor 8R3-9R8, P.O. Box - 336509, Dubai, UAE

is in accordance with the requirements of the following standard

ISO 9001:2015

(Quality Management System)

SCOPE

**The Procurement, Storage, Testing, Processing, Import and Export,
Distribution and Disposal of Stemcell and Tissues**

(IAF Code: 29,31,34,38)

Certificate Number : 020724019723

Initial Registration Date : 02-Jul-2024

1st Surveillance Date : 02-Jun-2025

2nd Surveillance Date : 02-Jun-2026

Certificate Expiry Date : 01-Jul-2027

To verify certificate, visit at :

www.arscert.com

www.uafaccreditation.org

www.iafcertsearch.org

Issued by ARS Assessment Private Limited


Managing Director



CB-MS-3923



UAF Address : 400, North Center Dr, STE 202, Norfolk, VA 23502, United States of America

This certificate remains the property of ARS and must be returned to ARS on Cancellation or Suspension of the certificate. Validity of the certificate is subject to successful completion of surveillance audits. Further clarification regarding the scope of this certificate and the applicability of standard may be obtained by consulting the Organisation on info@arscert.com

CERTIFICATE OF COMPLIANCE



This is to certify that

FUTURE HEALTH GCC FZ LLC

Building 64 - Al Razi Medical Complex, Ground Floor 8R3-9R8, Dubai, UAE, P.O. Box - 336509

is in accordance with the requirements of the following standard

ISO 15189: 2022
(Medical laboratories)

SCOPE OF CERTIFICATION

Medical Laboratory Testing in the following areas: Hematology, Microbiology, Serology

Certificate Number : **QCAS-FHG-24-051581646**

Initial Certification Date : **25 Oct 2024**

Date of Expiry : **24 Oct 2027**

1st Surveillance Date : **25 Sep 2025**

2nd Surveillance Date : **25 Sep 2026**

Verify the Certificate: <https://gaafs.us/site/search/>

Issued by QCAS Certifications Inc.




Managing Director



Queen's award

In April 2010 Future Health became the FIRST EVER cord blood storage operation to receive the prestigious Queen's Award for Enterprise, recognising our contribution to international trade. We have 29 offices around the world, collecting from over 51 different countries across 4 continents.

"We are delighted to have received a prestigious Queen's Award - not only to mark the impressive growth we have achieved but also to highlight stem cell banking as a valued and valuable UK industry. We very much hope that our international success will soon be replicated in the domestic market as we believe that all pregnant women should have the right to decide what happens to their baby's cord. We estimate that only a small number of cord blood samples are saved each year for public donation or private storage. However significant change is unlikely until there is a more uniformly positive attitude to cord collection in hospitals which will enable women to make an informed decision about whether to donate, store or discard the umbilical cord."

Roger Dainty MBE, Director of Future Health



Future Health Technologies Ltd, 10 Faraday Building, Nottingham Science & Technology Park, University Boulevard,
Nottingham, NG7 2QP, United Kingdom

رخصة منشأة صحية Health Facility License

تفاصيل الرخصة		اسم المنشأة (عربي)
Facility Name (Arabic)	فيوتشر هيلث جي سي سي منطقة حرة ذ.م.م	
Facility Name (English)	FUTURE HEALTH GCC FZ L.L.C	اسم المنشأة (إنجليزي)
DHA License No.	7381206	رقم رخصة هيئة الصحة بدبي
Facility Category	Cord Blood & Stem Cell Center	تصنيف المنشأة
License Status	Active	حالة الرخصة
License Issue Date	23-10-2024	تاريخ اصدار الرخصة
License Expiry Date	01-12-2025	تاريخ انتهاء الرخصة
Trade License Number	1074	رقم الرخصة التجارية

العنوان		اسم المنطقة
Area Name	Dubai Healthcare City	
Building Name	BUILDING 64- block F	اسم المبنى
Unit/Villa No.	G FLOOR	رقم الوحدة / الفيلا
Makani No.	N/A	رقم مكاني
Telephone No.	N/A	رقم الهاتف

أطراف الرخصة		الاسم
Type الصفة	Nationality الجنسية	Name الاسم
Owner	Jordan	AHMAD WASEF IBRAHIM AL AHMAD

المدير الطبي		الاسم
Medical/Clinical Director	SRUTI MARY JOSEPH	
Name	India	الجنسية

ملاحظات:

الملاحظات



License Details

تفاصيل الرخصة

License Number	1074	١٠٧٤	رقم الرخصة
Licensee	Future Health GCC FZ LLC	فيوتشر هيلث جي سي سي منطقة حرة-ذ.م.م	صاحب الرخصة
Trade Name	Future Health GCC FZ LLC	فيوتشر هيلث جي سي سي منطقة حرة-ذ.م.م	الإسم التجاري
Legal Status	Free Zone Limited Liability Company	شركة منطقة حرة ذات مسؤولية محدودة	الشكل القانوني
Company Manager	1 November, 2017	وفمبر ٢٠١٧	مدير الشركة
Expiry Date	29 October, 2025	٢٩ أكتوبر ٢٠٢٥	تاريخ الانتهاء

Name of Manager	Ahmad Wasef Ibrahim Alahmad	احمد واصف ابراهيم الاحمد	إسم مدير الشركة
-----------------	-----------------------------	--------------------------	-----------------

Address

العنوان

Address : 1	العنوان : 1
Premises : CA,8R3,9R8	المقر : CA,8R3,9R8
Floor : Ground	طابق : Ground
Building : 64 - Block F	المبني : بلوك اف - 64
Area Name : Dubai Healthcare City	إسم المنطقة : مدينة دبي الطبية

Activities

النشاطات

Non-Diagnostic Medical Laboratories	مختبرات طبية غير تشخيصية
• Stem Cell Processing/Storage Center	• مركز معالجة و تخزين الخلايا الجذعية
• Therapeutic Biological Product Manufacturing Laboratory	• مختبر منتجات بيولوجية علاجية

Current Issue Date	30 Oct 2024	Transaction type :	Commercial License Renewal	٣٠ أكتوبر ٢٠٢٤	تاريخ الإصدار الحالي
--------------------	-------------	--------------------	----------------------------	----------------	----------------------



Approved electronic document issued by Dubai Healthcare City Authority

Please be sure to renew your commercial license before expiry, as DHCR will impose a fine of AED 500 per month after 30 days of the commercial license expiry

Tax Registration Number (TRN) 100399738200003
Dubai Healthcare City Authority, P.O. Box: 66566, Dubai, UAE
T +971 4 383 8383 F +971 4 383 8384



وثيقة إلكترونية صادرة من سلطة مدينة دبي الطبية

يرجى التأكد من تجديد الرخصة قبل تاريخ الإنتهاء لتجنب دفع غرامة التأخير و التي تبلغ خمسمائة درهم عن كل شهر بعد 30 يوم من تاريخ الإنتهاء

رقم التسجيل الضريبي (TRN) 100399738200003
سلطة مدينة دبي الطبية ، ص.ب: 66566 ، دبي ، الإمارات العربية المتحدة
هاتف: +971 4 383 8383 فاكس: +971 4 383 8384



Future Health Technologies, Ltd - United Kingdom

having been assessed by AABB, has been found to meet the requirements of applicable Standards of this organization and therefore is granted this

CERTIFICATE OF ACCREDITATION

for the following activities:

Cell Therapy Activity: Cord Blood -Processing, Storage, and Distribution

In Witness whereof the undersigned, being duly authorized, have caused this Certificate to be issued and the AABB Corporate Seal to be affixed.

Effective Dates:

July 01, 2023 - June 30, 2025

A handwritten signature in black ink, reading "Brian A. Korman".

President, AABB

A handwritten signature in black ink, reading "P. Dayand Borge Jr.".

Chair, Accreditation Program Committee

Certificate of Registration

QUALITY MANAGEMENT SYSTEM - ISO 9001:2015

This is to certify that:

Future Health Technologies
10 Faraday Building
Nottingham Science & Technology Park
University Boulevard
Nottingham
NG7 2QP
United Kingdom

Holds Certificate Number:

FS 554566

and operates a Quality Management System which complies with the requirements of ISO 9001:2015 for the following scope:

The procurement, storage, testing, processing, import and export, distribution and disposal of stem cells and tissues.

For and on behalf of BSI:



Matt Page, Managing Director Assurance - UK & Ireland

Original Registration Date: 2010-01-21

Latest Revision Date: 2022-01-19

Effective Date: 2022-01-22

Expiry Date: 2025-01-21



Page: 1 of 1

...making excellence a habit.™

Licensing Number	22503
Licence Holder	Future Health Technologies Ltd
Licensed Premises	Future Health Technologies Ltd Unit 1 and Unit 10 Faraday Building Nottingham Science and Technology Park University Boulevard Nottingham NG7 2QP

Designated Individual Mrs Sarah Louise Reddish

This licence is granted under Regulation 7(1) and (2) and Schedule 2 of the Human Tissue (Quality and Safety for Human Application) Regulations 2007.

This licence authorises the following activities to be carried on only under the supervision of the Designated Individual

- (1) The procurement, testing, processing, distribution, import and/or export of tissues and/or cells intended for human application.
- (2) The storage of tissues and/or cells intended for human application

The licensed activity should be carried on only at the licensed premises specified above or, in the case of activities specified in paragraph (1) above, on any relevant third party premises.

This licence is subject to conditions set out in the Annexes accompanying this licence as may be subsequently varied pursuant to an application under paragraph 8 of Schedule 3 to the Human Tissue Act 2004.

This licence is valid from the date specified below and will remain in force until revoked.

S. Werhagauis

**Sharmila Nebhrajani OBE
Chair**

Bedwell

Sarah Bedwell
Director of Regulation

Valid From 23 November 2016

MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY

Blood Establishment Authorisation

SECTION 1

1. This authorisation is granted in accordance with the provisions of The Blood Safety and Quality Regulations 2005 No.50 (as amended).
2. It permits the authorisation holder named on page 3 of Section 1 to undertake the collection and testing of blood and blood components whatever their intended purpose and the processing, storage and distribution of blood and blood components when they are intended to be used for transfusion.
3. In this document a Blood Establishment Authorisation may be referred to as BEA and the Medicines and Healthcare products Regulatory Agency may be referred to as MHRA.
4. The authorisation holder must inform the MHRA, in advance, of any change to the details submitted by him and/or included in this authorisation. All changes must be approved by the MHRA to have effect. If the business should change hands, the company or person taking over the business will have to obtain a new authorisation before commencing the collection and testing of blood and blood components whatever their intended purpose and the processing, storage and distribution of blood and blood components when they are intended to be used for transfusion.

Attention is drawn to the structure of this authorisation (as detailed on page 2 of Section 1) and to its completeness in accord with that structure. This is of particular relevance where the holder of the authorisation is using it as evidence to a third party in support of claims to carry out those operations and activities to which this authorisation applies on premises and using personnel covered by this authorisation.



SECTION 1 (continued)

5. Authorisation Structure

This authorisation is divided into three sections.

- (a) Sections 1 (this section) identifies the authorisation holder and holds the authorising name for the issue of the authorisation. This section would not usually be replaced during routine variations of the authorisation unless the authorisation holder details are varied.
 - (b) Section 2 lists variations to the authorisation. A replacement section 2 will be issued each time the authorisation is varied.
 - (c) Section 3 contains the details relating to Responsible Person
 - (d) Section 4 contains the details relating to each site named on the authorisation. Where there is more than one site there will be more than one part to Section 4. When a variation is made to the details of a named the relevant portion of Section 4 will be replaced.
 - (e) The authorisation holder is required to attach to his authorisation any replacement pages issued by MHRA and to mark or destroy superseded pages as to render them invalid.
-

6. Provisions

- (a) The provisions of The Blood Safety and Quality Regulations 2005 No.50 (as amended).
 - (b) Additional conditions
 - (i)
 - (ii)
-



Licence reference: L0352-2-a

Licence for: Storage only

Centre reference: 0352

Centre name: Future Health Biobank

Licensed premises: Nottingham Science Park
Units 10-12 Faraday Building
University Boulevard Nottingham
Nottinghamshire
NG7 2QP

Person Responsible: Mrs Sarah Reddish

Licence Holder: Mrs Rachel Simpson

This Licence is granted under Section 11 of the Human Fertilisation and Embryology Act 1990 ('the Act') and is subject to conditions set out in the accompanying annexes. This Licence authorises the following activities to be carried out, at the above premises, under the supervision of the Person Responsible:

- Procuring embryos
- Processing embryos
- Distributing embryos
- Procuring gametes
- Processing gametes
- Distributing gametes
- Storage of embryos
- Storage of gametes
- Using embryos for the purpose of training persons in embryo biopsy, embryo storage or other embryological techniques

Signed



Peter Thompson
Chief Executive

Signed



Julia Chain
Chair

Valid from: 16/09/2021
Expires on: 15/09/2025

BEA NUMBER: BEA 21314

Version: 7

SECTION 1 (continued)

7. Authorisation Holder

(a) BEA Number: BEA 21314 has been granted to –

NAME:	MRS RACHEL SIMPSON
COMPANY:	FUTURE HEALTH TECHNOLOGIES LIMITED
TRADING AS:	
ADDRESS:	UNIT 10 FARADAY BUILDING, UNIVERSITY BOULEVARD, NOTTINGHAM SCIENCE & TECHNOLOGY PARK, NOTTINGHAM, NG7 2QP, UNITED KINGDOM

(b) This authorisation permits the holder to undertake the collection and testing of blood and blood components whatever their intended purpose and the processing, storage and distribution of blood and blood components when they are intended to be used for transfusion, at the premises and using the personnel in accordance with Sections 3 and 4 of this authorisation.

(c) This authorisation will continue to remain in force unless suspended or revoked by the Competent Authority or relinquished by the authorisation holder.

(d) Date granted - 25/01/2018

(e) Authorised by -

Name: Sean Kaiser

(A person authorised to approve on behalf of the Secretary of State for Health.)

Date: 25/01/2018



Autorisation n° 500028 / Requête n° 102587354

Annexe 1 : Fabrication de TrSt/TG/OGM

Adresse du site d'exploitation

Future Health Biobank SA
Route de Pra-de-Plan 3
1618 Châtel-St-Denis

Responsable technique

Gumy, Stéphane
Chimiste EHS

Activités autorisées / Conditions/Réserves

Fabrication de transplants standardisés

Produits de thérapie cellulaire :

Fabrication de produits intermédiaires de thérapie cellulaire ou de produits de thérapie cellulaire non prêts à l'emploi

- destinés à la transplantation autologue
- destinés à la transplantation allogénique

Produits tissulaires :

Fabrication de produits intermédiaires ou de produits tissulaires non prêts à l'emploi

- destinés à la transplantation autologue
- destinés à la transplantation allogénique

Limitée aux activités suivantes :

La fabrication est limitée au stockage des matières premières pour la fabrication des produits cellulaires et tissulaires prêts à l'emploi.



Autorisation n° 500028 / Requête n° 102587354

Annexe 2 : Commerce de gros de TrSt/TG/OGM

Adresse du site d'exploitation

Future Health Biobank SA
Route de Pra-de-Plan 3
1618 Châtel-St-Denis

Responsable technique

Gumy, Stéphane
Chimiste EHS

Activités autorisées / Conditions/Réserves

Commerce de gros de TrSt non prêts à l'emploi en tant que matières premières pour fabriquer des TrSt

- destinés à la transplantation autologue
- destinés à la transplantation allogénique



CERTIFICATE OF GMP COMPLIANCE

We certify herewith

that the company **Future Health Biobank SA, Route de Pra-de-Plan 3, 1618 Châtel-St-Denis, Switzerland**, has been duly authorized to manufacture and distribute transplant products, the manufacturing licence includes sterile products and includes the following product categories:

- not ready to use cell therapy products for autologous use or allogenic use
- not ready to use tissue products for autologous use or allogenic use

Restrictions:


Manufacturing is limited to storage of starting material for the manufacture of cell therapy products and tissue products

that the company is keeping the required level for good practices in the manufacture of transplant products according to the Swiss regulations in force. These regulations are in accordance with the requirements for good practices in the manufacture and quality control of the Pharmaceutical Inspection Convention /Co-operation Scheme (PIC/S) and the Directives of the European Commission;

that the manufacturing plant of the company is subject to official periodic inspections; the last regular inspection was conducted on **April 26 - 27, 2017**;

Berne, September 24, 2018
No. 18-2049

Swissmedic, Swiss Agency for
Therapeutic Products


Dr. Federico Cimini



Located at:



مدينة دبي الطبية
Dubai Healthcare City

FUTURE HEALTH GCC, DHCA license No. 1074, DHA license No.7381260

Dubai Health Care City, Building 64-Alrazi Medical Complex, Block F, Ground Floor 8R3-9R8,
P.O Box 336509, Dubai, UAE | 800-STEMCELL | T: +971 4 564 6292 | infoUAE@fhbb.com